治疗前低丰度HIV-1耐药变异对中国抗逆转录病毒治疗1年后病毒学失败的影响
在中国初治HIV-1感染者中开展巢式病例对照研究,比较43例病毒学失败者与100例对照者治疗前低丰度耐药变异对疗效的影响。结果显示2%-9%丰度的低丰度耐药变异与病毒学失败风险升高相关,≥10%耐药变异及突变负荷>1000拷贝/mL亦为预测因素。
要点
- 2%-9%丰度治疗前低丰度耐药变异与病毒学失败风险升高相关(校正OR 5.0)。
- ≥10%丰度耐药变异者病毒学失败风险升高(校正OR 8.0)。
- 突变负荷>1000拷贝/mL可预测病毒学失败(校正OR 7.2)。
核心结论
- 2%-9%丰度的治疗前低丰度耐药变异可增加病毒学失败风险,需进一步研究确定低丰度耐药变异的临床相关阈值及NRTI类低丰度耐药变异的作用。
研究设计与样本
- 在具有治疗前耐药基因型结果的HIV-1感染者中开展巢式病例对照研究,病例为ART 1年后病毒学失败(HIV-1 RNA载量≥1000拷贝/mL)者,对照为同一队列中病毒载量<1000拷贝/mL者。
- 采用下一代测序在10%、2%和1%检测阈值下鉴定低丰度治疗前耐药突变,突变负荷为耐药变异丰度与治疗前病毒载量的乘积,采用逻辑回归模型评估低丰度突变对病毒学失败的影响。
- 共纳入43例病例和100例对照进行分析。
主要发现
- 病例组治疗前耐药比例在不同检测阈值下均高于对照组:10%阈值44.2% vs 22.0%(P=0.007),2%阈值58.1% vs 31.0%(P=0.002),1%阈值90.7% vs 69.0%(P=0.006)。
- 与无治疗前耐药者相比,≥10%可检测治疗前耐药突变者病毒学失败风险升高(校正OR 8.0,95%CI 2.4-26.3,P=0.001)。
- 治疗前低丰度耐药变异(2%-9%丰度范围)者病毒学失败风险升高5倍(校正OR 5.0,95%CI 1.3-19.6,P=0.021)。
- 2%-9%丰度对NRTI耐药的变异和≥10%丰度对NNRTI耐药的变异分别与4倍和8倍病毒学失败风险相关。
- 突变负荷>1000拷贝/mL可预测病毒学失败(校正OR 7.2,95%CI 2.5-21.1,P=0.0003)。
局限性
- 需进一步研究确定低丰度耐药变异的临床相关阈值及NRTI类低丰度耐药变异的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the impact of pretreatment low-abundance HIV drug-resistant variants (LA-DRVs) on virological outcomes among ART-naive HIV-1-infected Chinese people who initiated ART. METHODS: A nested case-control study was conducted among HIV-1-infected individuals who had pretreatment drug resistance (PDR) genotypic results. Cases were defined as individuals with virological failure (HIV-1 RNA viral load ≥1000 copies/mL) after 1 year of ART, and controls were individuals from the same cohort whose viral load was less than 1000 copies/mL. Next-generation sequencing was used to identify low-abundance PDR mutations at detection thresholds of 10%, 2% and 1%. The mutant load was calculated by multiplying the abundance of HIV-1 drug-resistant variants by the pretreatment viral load. The impact of pretreatment low-abundance mutations on virological failure was estimated in logistic regression models. RESULTS: Participants (43 cases and 100 controls) were included in this study for the analysis. The proportion of participants with PDR was higher in cases than in controls at different detection thresholds (44.2% versus 22.0%, P = 0.007 at 10% threshold; 58.1% versus 31.0%, P = 0.002 at 2% threshold; 90.7% versus 69.0%, P = 0.006 at 1% threshold). Compared with participants without PDR, participants with ≥10% detectable PDR mutations were associated with an increased risk of virological failure (adjusted OR 8.0, 95% CI 2.4-26.3, P = 0.001). Besides this, individuals with pretreatment LA-DRVs (2%-9% abundance range) had 5-fold higher odds of virological failure (adjusted OR 5.0, 95% CI 1.3-19.6, P = 0.021). Furthermore, LA-DRVs at 2%-9% abundance resistant to NRTIs and mutants with abundance of ≥10% resistant to NNRTIs had a 4-fold and 8-fold risk of experiencing virological failure, respectively. It was also found that a mutant load of more than 1000 copies/mL was predictive of virological failure (adjusted OR 7.2, 95% CI 2.5-21.1, P = 0.0003). CONCLUSIONS: Low-abundance PDR mutations ranging from 2% to 9% of abundance can increase the risk of virological failure. Further studies are warranted to define a clinically relevant threshold of LA-DRVs and the role of NRTI LA-DRVs.
引用
- Li M, Song C, Hu J, et al. Impact of pretreatment low-abundance HIV-1 drug resistance on virological failure after 1 year of antiretroviral therapy in China. J Antimicrob Chemother. 2023. PMID: 37769159. doi:10.1093/jac/dkad297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。